ReviewAnnals of translational medicine2016
Prognostic biomarkers in acute coronary syndrome.
Review in Annals of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Gut microbial metabolite trimethylamine N-oxide as a novel predictor for adverse cardiovascular events after PCI: a systematic review and dose-response meta-analysis.Nutrition journal · 2025Pooled it
- Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis.Bioscience reports · 2019Pooled it
- Redox Imbalance and Coronary Complexity Linking Oxidative Stress Biomarkers to SYNTAX II Score in Acute Coronary Syndrome.Biomedicines · 2026Article
- Red cell distribution width and platelet indices as predictors of mortality in acute coronary syndrome: A prospective observational study.Bioinformation · 2026Article
- Platelet-to-Lymphocyte and Glucose-to-Lymphocyte Ratios as Prognostic Markers in Hospitalized Patients with Acute Coronary Syndrome.Journal of cardiovascular development and disease · 2025Article
- New cardiovascular disease markers in patients with familial hypercholesterolemia carriers of genetic variants.Journal of diabetes and metabolic disorders · 2025Article
- Growth Differentiation Factor 15 is Correlated With Urinary Markers in Patients with Chronic Heart Failure.Arquivos brasileiros de cardiologia · 2025Article
- Additional Benefits of Serum Oncostatin M Levels Compared to Cardiac Troponin in Non-ST Elevation Myocardial Infarction.Acta Cardiologica Sinica · 2024Article
- Targeting a Silent Disease: Vascular Calcification in Chronic Kidney Disease.International journal of molecular sciences · 2022Review
- Circulating Galectin-3 in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction Treated with Mild Hypothermia: A Biomarker Sub-Study of the SHOCK-COOL Trial.Journal of clinical medicine · 2022Article
- Individual variability in animal-specific hemodynamic compensation following myocardial infarction.Journal of molecular and cellular cardiology · 2022Article
- Plasma trimethylamine-N-oxide, its precursors and risk of cardiovascular events in patients with acute coronary syndrome: Mediating effects of renal function.Frontiers in cardiovascular medicine · 2022Article
- Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus.Cardiovascular diabetology · 2021Observational
- Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease.Frontiers in cardiovascular medicine · 2021Review
- Post-Myocardial Infarction Ventricular Remodeling Biomarkers-The Key Link between Pathophysiology and Clinic.Biomolecules · 2020Review
- Could sST2 Predict Contrast-Induced Nephropathy in ST-Segment Elevation Myocardial Infarction?International journal of general medicine · 2020Article
- Galectin-3 Is a Potential Mediator for Atherosclerosis.Journal of immunology research · 2020Review
- Growth Differentiation Factor-15 Levels at Admission Provide Incremental Prognostic Information on All-Cause Long-term Mortality in ST-Segment Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention.Cardiology and therapy · 2019Article
- Galectin-3 and risk of ischaemic stroke: Reasons for Geographic and Racial Differences in Stroke cohort.European journal of neurology · 2017Article
- Galectin-3 in Peripheral Artery Disease. Relationships with Markers of Oxidative Stress and Inflammation.International journal of molecular sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acute coronary syndrome (ACS) is a leading cause of death around the globe. Beside a still high mortality rate, additional complications of ACS include arrhythmias, left ventricular mural thrombus, cardiac fibrosis, heart failure (HF), cardiogenic shock, mitral valve dysfunction, aneurysms, up to cardiac rupture. Despite many prognostic tools have been developed over the past decades, efforts are still ongoing to identify reliable and predictive biomarkers, which may help predict the prognosis of these patients and especially the risk of HF. Recent evidence suggests that the value of a discrete number of biomarkers of myocardial fibrosis, namely the soluble form of suppression of tumorigenicity 2 (sST2) and galectin-3 (GAL-3), may be predictive of HF and death in patients with ACS. Interestingly, the already promising predictive value of these biomarkers when measured alone was shown to be consistently magnified when combined with other and well-established cardiac biomarkers such natriuretic peptides and cardiac troponins. This article is hence aimed to review the current knowledge about cardiac biomarkers of fibrosis and adverse remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.